Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Androgen deprivation therapy is a common treatment for prostate cancer, but metastatic castration-resistant prostate cancer (CRPC) remains incurable.
• Loss of PTEN (phosphatase and tensin homolog) is frequent in CRPC, leading to PI3K pathway activation.
• Understanding CRPC metastasis mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of the PI3K pathway, specifically the p110β isoform, in CRPC cell migration and invasion.
• To evaluate the potential of targeting the p110β-PAK1 axis as a therapeutic strategy for CRPC.

Main Methods:

• Generated a PTEN-null, androgen-independent prostate cancer cell line (PKO) from transgenic mice.
• Assessed PKO cell migration and invasion in vitro under androgen deprivation.
• Utilized pharmacological inhibitors to target the p110β-PAK1 axis.
• Analyzed PAK1 activation and its correlation with patient survival using clinical samples.

Main Results:

• Androgen deprivation enhanced PKO cell migration/invasion via p110β-PAK1-MAPK activation.
• Inhibition of the p110β-PAK1 axis significantly reduced prostate cancer cell migration/invasion.
• PAK1 activation was higher in CRPC compared to advanced prostate cancer.
• Elevated PAK1/phosphorylated-PAK1 levels correlated with decreased survival in CRPC patients.

Conclusions:

• The p110β-PAK1 axis plays a critical role in CRPC cell migration and invasion.
• Targeting the p110β-PAK1 axis represents a promising therapeutic strategy for CRPC metastasis.
• The generated PKO cell line is a valuable model for studying CRPC initiation and progression.